Active ingredientOxaliplatinCat. No. P-O047-001CAS 61825-94-3Family · Pharmaceutical analytical standards
Oxaliplatin
A platinum-based anticancer drug developed in the 1970s in Japan by Yoshinori Kidani at Nagoya City University; approved in Europe in 1996 and in the United States in 2002, it is used mainly for colorectal cancer. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.
Did you know?Compared with cisplatin and carboplatin, the two amine groups bound to platinum are replaced by a single diaminocyclohexane ring, while an oxalate group completes the structure.
Go to the active ingredient →Active ingredientOxaliplatinCat. No. P-O047-001CAS 61825-94-3
Pharmacopoeial impurityOxaliplatin EP Impurity CCat. No. P-O047-003CAS 111321-67-6
Pharmacopoeial impurityOxaliplatin EP Impurity DCat. No. P-O047-004CAS 61758-77-8
Pharmacopoeial impurityOxaliplatin EP Impurity BCat. No. P-O047-005CAS 89955-85-1
Isotopically labelledOxaliplatin-d10Cat. No. P-O047-007
ImpurityOxaliplatin Impurity 1Cat. No. P-O047-008CAS 111263-58-2
Pharmacopoeial impurityOxaliplatin EP Impurity E DinitrateCat. No. P-O047-009CAS 82398-34-3
Impurity(R,R)-Dichloro(1,2-diaminocyclohexane)platinum(II)Cat. No. P-O047-011CAS 61848-66-6No product matches your search.
EDQM standards 5
The official European Pharmacopoeia standards for this family.
Reference substanceDichlorodiaminocyclohexaneplatinum CRSEDQM code Y0000275Family OxaliplatinReference substanceOxaliplatin CRSEDQM code Y0000271Family OxaliplatinImpurityOxaliplatin impurity B CRSEDQM code Y0000272Family OxaliplatinImpurityOxaliplatin impurity C CRSEDQM code Y0000273Family OxaliplatinImpurityOxaliplatin impurity D CRSEDQM code Y0000274Family OxaliplatinNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.